References
- Li C, Wang Y. Factors associated with early diagnosis in pediatric vs adult nasopharyngeal carcinoma. Acta Otolaryngol. 2018;138:56–59.
- Hsin CH, Tseng HC, Lin HP, et al. Sinus mucosa status in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a 5-year follow-up. Head Neck. 2016;38:29–35.
- Sun D, Zhao M, Yin J, et al. Vestibular function disorders and potential mechanisms in irradiation nasopharyngeal carcinoma patients. Acta Otolaryngol. 2016;136:759–763.
- Huang TL, Chien CY, Tsai WL, et al. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck. 2016;38:E1026–E1032.
- Wang J, Chen YY, Tai A, et al. Sensorineural hearing loss after combined intensity modulated radiation therapy and Cisplatin-based chemotherapy for nasopharyngeal carcinoma. Transl Oncol. 2015;8:456–462.
- Wang SZ, Wang WF, Zhang HY, et al. Analysis of anatomical factors controlling the morbidity of radiation-induced otitis media with effusion. Radiother Oncol. 2007;85:463–468.
- Lee AW, Ng WT, Chan LL, et al. Evolution of treatment for nasopharyngeal cancer-success and setback in the intensity-modulated radiotherapy era . Radiother Oncol. 2014;110:377–384.
- Yeh SA, Tang Y, Lui CC, et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005;62:672–679.
- Yao JJ, Zhou GQ, Lin L, et al. Dose–volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma. Sci Rep. 2015;5:13525.
- Zeng L, Tian YM, Sun XM, et al. Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. Br J Cancer. 2014;110:49–54.
- Hsin CH, Chen TH, Young YH, et al. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients. Otolaryngol Head Neck Surg. 2010;143:662–668.
- Petsuksiri J, Sermsree A, Thephamongkhol K, et al. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. Radiat Oncol. 2011;6:19.
- Chan SH, Ng WT, Kam KL, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys. 2009;73:1335–1342.
- Zuur CL, Simis YJ, Lamers EA, et al. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2009;74:490–496.
- Low WK, Tan MG, Chua AW, et al. 12Th Yahya Cohen Memorial Lecture: the cellular and molecular basis of radiation-induced sensori-neural hearing loss. Ann Acad Med Singapore. 2009;38:91–94.
- Jereczek-Fossa BA, Zarowski A, Milani F, et al. Radiotherapy-induced ear toxicity. Cancer Treat Rev. 2003;29:417–430.
- Wang SZ, Li J, Miyamoto CT, et al. A study of middle ear function in the treatment of nasopharyngeal carcinoma with IMRT technique. Radiother Oncol. 2009;93:530–533.
- Kujawski OB, Poe DS. Laser eustachian tuboplasty. Otol Neurotol. 2004;25:1–8.
- Hsin CH, Chen TH, Liang KL, et al. Postirradiation otitis media with effusion in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy. Laryngoscope. 2013;123:2148–2153.
- Zhang J, Wang Y, Duan Y, et al. PKCα promotes local advancement via its dual roles in nasopharyngeal carcinoma. Acta Otolaryngol. 2017;137:662–667.